SLCO1B1型
阿托伐他汀
冠状动脉疾病
他汀类
内科学
医学
基因分型
药理学
糖尿病
心脏病学
胆固醇
基因型
药物遗传学
内分泌学
生物
基因
生物化学
作者
Govindaswamy Bharath,Vishnuprabu Durairaj Pandian,Preethi Loganathan,Arumugam Suriyam Nagappan,Ramia Thiagaraja Dhianeshwaran Isravanya,Lakkakula Vks Bhaskar,Swaminathan Nagarajan,Arasambattu Kannan Munirajan
出处
期刊:Pharmacogenomics
[Future Medicine]
日期:2022-08-01
卷期号:23 (12): 683-694
被引量:1
标识
DOI:10.2217/pgs-2022-0044
摘要
Introduction: Atorvastatin exhibits wide interindividual variability in treatment response, limiting the drug efficacy in coronary artery disease patients. Aim: To study the effect of genetic variants involved in atorvastatin transport/metabolism and correlate their lipid-lowering efficacy. Materials & methods: Genotyping was performed using 5′-hydrolysis probe method (n = 412), and the study evaluated the treatment response in 86 patients. Results: Significant reduction in total cholesterol and low-density lipoprotein cholesterol (LDL-C) were observed in SLCO1B1-rs4149056, rs4363657 and ABCB1-rs1045642 genotypes. The combined genotypes of ABCB1 and SLCO1B1 showed a strong synergistic effect in reducing the total cholesterol and LDL-C. Diabetes and smoking were observed to influence the LDL-C reduction. Conclusion: The genetic variants of SLCO1B1 and ABCB1 predict the lipid-lowering efficacy of atorvastatin, and this may be useful in genotype-guided statin therapy for coronary artery disease patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI